CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
38 hedge funds and large institutions have $11.8M invested in CASI Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
178% more capital invested
Capital invested by funds: $4.23M → $11.8M (+$7.54M)
36% more funds holding
Funds holding: 28 → 38 (+10)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0.16% more ownership
Funds ownership: 0.4% → 0.55% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.57M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$509K |
| 3 |
BlackRock
New York
|
+$258K |
| 4 |
PA
Perceptive Advisors
New York
|
+$227K |
| 5 |
Barclays
London,
United Kingdom
|
+$181K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSC
Wellington Shields & Co
New York
|
-$122K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$95.2K |
| 3 |
VF
Virtu Financial
New York
|
-$77.9K |
| 4 |
HCM
Howland Capital Management
Boston,
Massachusetts
|
-$43K |
| 5 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$27K |
CASI Hedge Fund Activity: Q4 2017 in Review
38 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2017, worth a combined $11.8M — up 178% from $4.23M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CASI positions and 2 closed out — a net gain of 10 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.57M. The largest seller was Wellington Shields & Co, cutting an estimated $122K.
- 38 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2017, up from 28 in Q3 2017.
- Funds reported $11.8M of CASI Pharmaceuticals stock for Q4 2017, up 178% quarter-over-quarter.
- 12 funds opened new CASI Pharmaceuticals positions in Q4 2017 and 2 closed out, a net change of +10 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2017 was Vanguard Group, an estimated $1.57M added.
- The largest CASI Pharmaceuticals seller in Q4 2017 was Wellington Shields & Co, an estimated $122K sold.
Based on aggregated 13F filings for Q4 2017.